Life Biosciences just dosed the first human patient with ER-100 — an OSK gene therapy built from three Yamanaka factors, designed to reprogram old cells back toward a younger state. The first target is the eye. But the real implication is much bigger: this method appears to work on every tissue type it has been tried on.
If this first eye trial comes back safe, it could be the first domino in a much larger age-reversal wave: eye, liver, brain, skin, muscle, heart, kidney, blood vessels — potentially every tissue in the body.
This episode reveals the tidal wave of companies racing toward human trials using the same basic strategy: epigenetically reprogramming old cells so they behave young again. Billions of dollars are pouring into this from Jeff Bezos, Sam Altman, Brian Armstrong, Peter Thiel, and the biggest names in longevity biotech.
We walk through who they are, what they are trying to cure, why the eye came first, what worked in mice and monkeys, why NewLimit is going after liver rejuvenation, and whether the cheap pill version could be right behind the expensive gene therapy.
Bottom line: real age reversal is now in a human trial.
LONGEVITY LATTE PRE-ORDER:







